Assessment of Th17 lymphocytes and cytokine IL‑17A in epithelial ovarian tumors

Winkler,Izabela; Pyszniak,Maria; Pogoda,Katarzyna; Semczuk,Andrzej; Gogacz,Marek; Miotla,Paweł; Adamiak,Aneta; Darmochwal‑Kolarz,Dorota; Rechberger,Tomasz; Tabarkiewicz,Jacek

doi:10.3892/or.2017.5559

Assessment of Th17 lymphocytes and cytokine IL‑17A in epithelial ovarian tumors

Authors:
- Izabela Winkler
- Maria Pyszniak
- Katarzyna Pogoda
- Andrzej Semczuk
- Marek Gogacz
- Paweł Miotla
- Aneta Adamiak
- Dorota Darmochwal‑Kolarz
- Tomasz Rechberger
- Jacek Tabarkiewicz
View Affiliations

Affiliations: Second Department of Gynecology, Lublin Medical University, 20-954 Lublin, Poland, Postgraduate School of Molecular Medicine, Warsaw Medical University, 02-091 Warsaw, Poland, Centre for Innovative Research in Medical and Natural Sciences, Medical Faculty of the University of Rzeszów, 35-959 Rzeszów, Poland
Published online on: April 6, 2017 https://doi.org/10.3892/or.2017.5559
Pages: 3107-3115

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was carried out to assess the percentage of T helper 17 (Th17) lymphocytes in blood and tissue and IL-17A serum concentrations in patients with epithelial ovarian tumors. Two isoforms, IL-17A and IL-17F, as well as IL-21 and IL-22, were simultaneously investigated. The study group consisted of 60 women affected by epithelial ovarian tumors (benign, borderline and malignant) and 20 women without ovarian pathology as a control group. The evaluation of the percentage of Th17 cells secreting IL-17A, IL-17F, IL-21 and IL-22 in peripheral blood and tumor tissues was performed using flow cytometry applying a Th17 cytokine staining panel. The blood serum concentration of IL-17A was determined using ELISA. We found no statistically significant differences in the subpopulations of Th17 lymphocytes, either in peripheral blood or in ovarian tissues, following comparison of the women with and without ovarian pathology. Negative correlations were found between the percentage of CD4+/IL-21+ (rs=0.8, p=0.02) and CD4+/IL-17+ (rs=-0.78, p=0.03) in the tissue and IL-17A in blood serum in the group of patients with borderline ovarian tumors. A negative correlation was also found between IL-17A and the percentage of CD4+/IL-21+ in peripheral blood (rs=‑0.48, p=0.03) in the group of patients with ovarian cancer. The increased percentage of Th17 cells in tissue was not correlated with the overall survival of the ovarian cancer patients. In conclusion, we showed that more Th17 cells secreted IL-17A and IL-21 in the tissue of borderline ovarian tumors and less IL-17A in serum. We also observed that in peripheral blood of the patients with ovarian cancer, there was a higher percentage of Th17 lymphocytes and a lower concentration of IL-17A in serum indicating a negative correlation. An increased percentage of Th17 cells in ovarian tissue does not influence the time of survival of patients with ovarian cancer.

View Figures

View References

1	Romagnani S: Human Th17 cells. Arthritis Res Ther. 10:2062008. View Article : Google Scholar : PubMed/NCBI
2	Iwakura Y, Nakae S, Saijo S and Ishigame H: The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 226:57–79. 2008. View Article : Google Scholar : PubMed/NCBI
3	Søndergaard H and Skak K: IL-21: Roles in immunopathology and cancer therapy. Tissue Antigens. 74:467–479. 2009. View Article : Google Scholar : PubMed/NCBI
4	Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC and Matthys P: Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 60:390–395. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zenewicz LA and Flavell RA: IL-22 and inflammation: Leukin' through a glass onion. Eur J Immunol. 38:3265–3268. 2008. View Article : Google Scholar : PubMed/NCBI
6	Duhen T, Geiger R, Jarrossay D, Lanzavecchia A and Sallusto F: Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 10:857–863. 2009. View Article : Google Scholar : PubMed/NCBI
7	Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW and Dong C: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31:787–798. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM, Hoft DF and Peng G: Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-γ⁺ and FOXP3⁺ T cells with potent suppressive function. Eur J Immunol. 41:936–951. 2011. View Article : Google Scholar : PubMed/NCBI
11	Fialová A, Partlová S, Sojka L, Hromádková H, Brtnický T, Fučíková J, Kocián P, Rob L, Bartůňková J and Spíšek R: Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer. 132:1070–1079. 2013. View Article : Google Scholar : PubMed/NCBI
12	Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J and Wang RF: Generation and regulation of human CD4⁺ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA. 105:15505–15510. 2008. View Article : Google Scholar : PubMed/NCBI
13	Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, et al: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
14	Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, et al: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59:3698–3704. 1999.PubMed/NCBI
15	Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J and Liu J: High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res. 352:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
16	Brandt K, Bulfone-Paus S, Foster DC and Rückert R: Interleukin-21 inhibits dendritic cell activation and maturation. Blood. 102:4090–4098. 2003. View Article : Google Scholar : PubMed/NCBI
17	Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC and Stockinger B: The aryl hydrocarbon receptor links T_H17-cell-mediated autoimmunity to environmental toxins. Nature. 453:106–109. 2008. View Article : Google Scholar : PubMed/NCBI
18	Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, et al: IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 491:259–263. 2012. View Article : Google Scholar : PubMed/NCBI
19	Sabat R, Ouyang W and Wolk K: Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 13:21–38. 2014. View Article : Google Scholar : PubMed/NCBI
20	Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E and Fabbri P: Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: A randomized-controlled trial. J Clin Immunol. 29:210–214. 2009. View Article : Google Scholar : PubMed/NCBI
21	Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R and Zhu B: Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133⁺ cancer stem-like cells in ovarian cancer. Oncogene. 34:165–176. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, et al: IL-22⁺CD4⁺ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 40:772–784. 2014. View Article : Google Scholar : PubMed/NCBI
23	Gogacz M, Winkler I, Bojarska-Junak A, Tabarkiewicz J, Semczuk A, Rechberger T and Adamiak A: Increased percentage of Th17 cells in peritoneal fluid is associated with severity of endometriosis. J Reprod Immunol. 117:39–44. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wei L, Laurence A, Elias KM and O'Shea JJ: IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 282:34605–34610. 2007. View Article : Google Scholar : PubMed/NCBI